Skip to content
Bored Studies
RecruitingPhase 3

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

Annexon, Inc. · NCT07020819

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 8–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
30
US sites recruiting
22
Study start
September 12, 2025
Record last updated
October 26, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.

Being studied: Tanruprubart

Conditions: Guillain-Barre Syndrome

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.
  • Onset of GBS-related weakness ≤10 days before start of infusion on Day 1
  • GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.

Key Exclusion Criteria

  • Previous or planned treatment with either plasma exchange or IV immunoglobulin within 90 days of Day 1.
  • Diagnosis of any form of GBS that does not involve weakness of the extremities.

Other protocol-defined criteria may apply.

Recruiting US locations

Study contacts (from the official record)

  • Study Coordinator · 1-650-822-5500 · clinicaltrials@annexonbio.com
An Open Label Clinical Study to Evaluate Tanruprubart (Also… (NCT07020819) | Bored Studies